Skip to content

4D Molecular Therapeutics

US · FDMT #3519 by market cap Listed 2020
10.23 -0.49 -4.57%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 10.44 -2.61%
After-hours 10.23 0.00%
16.768.6410.232026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on FDMT?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is -18.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 19.7% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days C → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Operating margin -187.2% Better than 5%
Net margin -164.4% Better than 6%
Return on equity -27.6% Better than 14%
Return on invested capital -30.0% Better than 10%
Momentum C+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -35.4% Better than 14%
6-month return 19.0% Better than 82%
12-month return (ex latest month) 9.3% Better than 45%
Distance below 52-week high 39.6% Better than 29%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 9.4x Better than 93%
Debt to assets 3.8% Better than 82%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 85.7% Better than 67%
Upside to average target 183.5% Better than 93%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -16.35%
1M -21.91%
3M -36.46%
6M +20.78%
YTD +36.40%
1Y -1.06%
3Y -17.43%
5Y -55.64%

Key statistics

Price & volume

Prev close
10.72
Open
10.36
Day range
10.11 - 10.94
Avg price
10.34
Volume
690.97K
Turnover
7.14M
Amplitude
7.72%
52-week range
6.96 - 16.93

Valuation

P/E
-4.23
P/E (TTM)
-3.79
P/B
1.71
EPS
-2.42
Net profit
-136.44M
Net assets
337.94M

Share structure

Market cap
576.76M
Float cap
449.48M
Shares out
56.38M
Float shares
43.94M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-12-11
52-week range 33% of range
6.96 16.93

39.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-705.86K net over the window

Short interest

Shares short
10.90M
As of
2026-10-30

Frequently asked questions

What is the current stock price of 4D Molecular Therapeutics (FDMT)?

4D Molecular Therapeutics last traded at 10.23. This page shows a periodic quote snapshot. Check the displayed quote time.

What is 4D Molecular Therapeutics's market cap?

About 576.76M.

What is the P/E ratio of 4D Molecular Therapeutics?

The trailing twelve-month P/E is -3.79. The Valuation tab shows it against the stock's own five-year range.

Does 4D Molecular Therapeutics pay a dividend?

4D Molecular Therapeutics does not currently pay a regular dividend.

Is 4D Molecular Therapeutics a buy according to analysts?

The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 29.00, which implies 183.5% upside from the current price. This is not investment advice.

What is 4D Molecular Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates 4D Molecular Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

4D Molecular Therapeutics discussion 0 comments

Add a comment